More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...
Abstract and Introduction Review of Normal Platelet Physiology and Megakaryocytopoisis Qualitative Platelet Abnormalities Conclusion References Nitric oxide (NO) is another drug used in the neonatal ...
Ianalumab, a monoclonal antibody, helped patients with immune thrombocytopenia (ITP) maintain safe platelet counts without ...
Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...
News-Medical.Net on MSN
Research ushers in a new era of hope for patients with primary immune thrombocytopenia
More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...
A late-breaking presentation at the American Society of Hematology (ASH) 2025 meeting revealed promising phase 3 findings for ...
Biomedical engineers report a new application for their synthetic platelets: treating the genetic condition that prevents blood from clotting, Von Willebrand disease (VWD). The most common of all ...
More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia were able to maintain safe ...
Inherited platelet disorders represent a heterogeneous group of genetic conditions that affect the number, size, or function of platelets, with clinical manifestations ranging from mild mucocutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback